Dopamine receptors and l-dopa-induced dyskinesia

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages

  Berthet, Amandine ^a   Bezard, Erwan ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Abnormal involuntary movements; Dopamine D1 receptor; l dopa; Parkinson's disease; Sensitization; Signalling cascade; Trafficking

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; BENSERAZIDE; CLOZAPINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; NALOXONE; YOHIMBINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ARTICLE; DYSKINESIA; GABAERGIC SYSTEM; GLOBUS PALLIDUS; HUMAN; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUTAMEN; THALAMOCORTICAL TRACT; ANIMAL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE; RECEPTORS, DOPAMINE; SIGNAL TRANSDUCTION;

EID: 72649085036     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70827-2     Document Type: Article

References (53)

1. Ehringer H., and Hornykiewicz O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.]. Klin Wochenschr 38 (1960) 1236-1239
2. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
3. Obeso J.A., Rodríguez-Oroz M.C., Rodríguez M., Lanciego J.L., Artieda J., Gonzalo N., et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23 10 Suppl (2000) S8-19
4. Cotzias G.C., Papavasiliou P.S., and Gellene R. Modification of Parkinsonism - chronic treatment with L-dopa. N Engl J Med 280 (1969) 337-345
5. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2 (2001) 577-588
6. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9 (2008) 665-677
7. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Dopamine receptors: from structure to function. Physiol Rev 78 (1998) 189-225
8. Le Moine C., and Bloch B. D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol 355 (1995) 418-426
9. Landwehrmeyer B., Mengod G., and Palacios J.M. Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res 18 (1993) 187-192
10. Landwehrmeyer B., Mengod G., and Palacios J.M. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci 5 (1993) 145-153
11. Diaz J., Lévesque D., Griffon N., Lammers C.H., Martres M.P., Sokoloff P., et al. Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur J Neurosci 6 (1994) 1384-1387
12. Diaz J., Lévesque D., Lammers C.H., Griffon N., Martres M.P., Schwartz J.C., et al. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience 65 (1995) 731-745
13. Bouthenet M.L., Souil E., Martres M.P., Sokoloff P., Giros B., and Schwartz J.C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 564 (1991) 203-219
14. Lévesque D., Diaz J., Pilon C., Martres M.P., Giros B., Souil E., et al. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89 (1992) 8155-8159
15. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., and Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94 (1997) 3363-3367
16. Bézard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9 (2003) 762-767
17. Alexander G.E., and Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13 (1990) 266-271
18. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma Jr. F.J., et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
19. Nadjar A., Brotchie J.M., Guigoni C., Li Q., Zhou S.B., Wang G.J., et al. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. J Neurosci 26 (2006) 8653-8661
20. Di Chiara G., Morelli M., Barone P., and Pontieri F. Priming as a model of behavioural sensitization. Dev Pharmacol Ther 18 (1992) 223-227
21. Morelli M., Fenu S., Garau L., and Di Chiara G. Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. Eur J Pharmacol 162 (1989) 329-335
22. Morelli M., and Di Chiara G. Agonist-induced homologous and heterologous sensitization to D-1-and D-2-dependent contraversive turning. Eur J Pharmacol 141 (1987) 101-107
23. Cenci M.A., Lee C.S., and Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10 (1998) 2694-2706
24. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15 (2002) 120-132
25. Berke J.D., Paletzki R.F., Aronson G.J., Hyman S.E., and Gerfen C.R. A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 18 (1998) 5301-5310
26. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6 (2003) 501-506
27. Aubert I., Guigoni C., Håkansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 (2005) 17-26
28. Corvol J.C., Muriel M.P., Valjent E., Féger J., Hanoun N., Girault J.A., et al. Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci 24 (2004) 7007-7014
29. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.A., et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27 (2007) 6995-7005
30. Guigoni C., Doudnikoff E., Li Q., Bloch B., and Bezard E. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis 26 (2007) 452-463
31. Berthet A., Porras G., Doudnikoff E., Stark H., Cador M., Bezard E., et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci 29 (2009) 4829-4835
32. Bezard E., Gross C.E., Qin L., Gurevich V.V., Benovic J.L., and Gurevich E.V. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol Dis 18 (2005) 323-335
33. Ahmed M.R., Bychkov E., Gurevich V.V., Benovic J.L., and Gurevich E.V. Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment. J Neurochem 104 (2008) 1622-1636
34. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 48 (2005) 503-516
35. Silverdale MA, Kobylecki C, Hallett PJ, Li Q, Dunah AW, Ravenscroft P, et al. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned non-human primate. Synapse In press 2009.
36. Bordet R., Ridray S., Schwartz J.C., and Sokoloff P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12 (2000) 2117-2123
37. Gross C.E., Ravenscroft P., Dovero S., Jaber M., Bioulac B., and Bezard E. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J Neurochem 84 (2003) 1246-1255
38. Fiorentini C., Busi C., Gorruso E., Gotti C., Spano P., and Missale C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74 (2008) 59-69
39. Marcellino D., Ferré S., Casadó V., Cortés A., Le Foll B., Mazzola C., et al. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem 283 (2008) 26016-26025
40. Visanji N.P., Fox S.H., Johnston T., Reyes G., Millan M.J., and Brotchie J.M. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiol Dis 35 (2008) 184-192
41. Ahmed MR, Berthet A, Bychkov E, Li Q, Porras G, Bioulac BH, et al. Lentivirally-mediated overexpression of GRK6 alleviates L-DOPA-induced dyskinesia in experimental Parkinson's disease. 2009. In revision.
42. Brambilla R. Targeting Ras/ERK signaling in the striatum: will it help?. Mol Psychiatry 8 (2003) 366-368
43. Mazzucchelli C., Vantaggiato C., Ciamei A., Fasano S., Pakhotin P., Krezel W., et al. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron 34 (2002) 807-820
44. Valjent E., Corvol J.C., Pages C., Besson M.J., Maldonado R., and Caboche J. Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J Neurosci 20 (2000) 8701-8709
45. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci USA 102 (2005) 491-496
46. Gerfen C.R., Miyachi S., Paletzki R., and Brown P. D1 dopamine receptor super-sensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22 (2002) 5042-5054
47. Westin J.E., Vercammen L., Strome E.M., Konradi C., and Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62 (2007) 800-810
48. Schuster S., Nadjar A., Guo J.T., Li Q., Ittrich C., Hengerer B., et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J Neurosci 28 (2008) 4311-4316
49. Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 61 11 Suppl 6 (2003) S32-S38
50. Rahman Z., Schwarz J., Gold S.J., Zachariou V., Wein M.N., Choi K.H., et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 38 (2003) 941-952
51. Rahman Z., Gold S.J., Potenza M.N., Cowan C.W., Ni Y.G., He W., et al. Cloning and characterization of RGS9-2: a striatal-enriched alternatively spliced product of the RGS9 gene. J Neurosci 19 (1999) 2016-2026
52. Gold S.J., Hoang C.V., Potts B.W., Porras G., Pioli E., Kim K.W., et al. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci 27 (2007) 14338-14348
53. Tekumalla P.K., Calon F., Rahman Z., Birdi S., Rajput A.H., Hornykiewicz O., et al. Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatry 50 (2001) 813-816